Laserfiche WebLink
Table of Contents <br />I. INTRODUCTION <br />4 <br />1. <br />Development of "Combined" Plan <br />4 <br />2. <br />Approach <br />4 <br />3. <br />Background <br />5 <br />H. GENERAL <br />5 <br />1. <br />Scope <br />5 <br />2. <br />Applicability <br />6 <br />3. <br />Compliance <br />6 <br />4.' <br />"DOT" vs. "PHMSA" <br />6 <br />5. <br />DOT Procedures <br />6 <br />6. <br />Stand -down Waiver <br />6 <br />7. " <br />Preemption of State and Local Laws <br />6 <br />8. <br />Definitions <br />7 <br />III. POLICY AND RESPONSIBILITIES <br />12 <br />1. <br />Company Policy <br />12 <br />2. <br />Responsibilities of Key Personnel <br />12 <br />3. <br />Responsibility of Covered Employees <br />13 <br />4. <br />Use of Service Agents <br />13 <br />5. <br />Critical Service Agent Positions <br />13 <br />6. <br />"NON -DOT" Testing Program <br />14 <br />IV. DOT PROGRAM REQUIREMENTS <br />14 <br />1. <br />Employees Subject to Testing <br />14 <br />2. <br />Acknowledgement/Receipt Form <br />14 <br />3. <br />History -check Requirement <br />14 <br />4. <br />Employee Notification of Tests <br />15 <br />5. <br />DOT Drug Violations <br />15 <br />6. <br />DOT Alcohol Violations and Prohibited Conduct <br />16 <br />7. <br />Violation Consequences and Company Actions <br />16 <br />V. ANTI -DRUG PROGRAM <br />17 <br />1. <br />DOT -Required Drug Tests <br />17 <br />2. <br />Drug Tests That Require Direct Observation Procedures <br />19 <br />3. <br />Specimen Collection Procedures <br />20 <br />4. <br />PHMSA Inspection Protocol for Specimen Collection Sites <br />21 <br />5. <br />Drug Testing Laboratory <br />22 <br />6. <br />Laboratory Retention Periods and Reports <br />24 <br />7. <br />Laboratory Quality Control <br />24 <br />S. <br />MRO Review of Drug Test Results <br />24 <br />9. <br />Split Specimen Testing <br />25 <br />10. <br />Medical Marijuana <br />26 <br />J. RANCK ELECTRIC, INC. <br />PHMSA DRUG/ALCOHOL PLAN <br />NATIONAL COMPI IANCF- MANAGFMENTSFRVICF, INC, (NCRAS) 2b10 <br />